Vaxcyte annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Vaxcyte Stock-Based Compensation Growth & History (PCVX)
Vaxcyte's stock-based compensation was $138.8M for fiscal 2025.
View full Vaxcyte company overviewVaxcyte annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $138.8M | $54.0M | +63.69% |
| 2024 | 2024-12-31 | $84.8M | $36.1M | +73.96% |
| 2023 | 2023-12-31 | $48.8M | $25.1M | +106.17% |
| 2022 | 2022-12-31 | $23.6M | $12.9M | +120.43% |
| 2021 | 2021-12-31 | $10.7M | $5.3M | +97.44% |
| 2020 | 2020-12-31 | $5.4M | $4.2M | +358.57% |
| 2019 | 2019-12-31 | $1.2M | $436,000 | +58.21% |
| 2018 | 2018-12-31 | $749,000 | — | — |
Vaxcyte quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $41.2M | $4.3M | +11.68% |
| Q1 2026 | 2026-03-31 | $38.0M | $7.3M | +24.00% |
| Q4 2025 | 2025-12-31 | $36.0M | $11.6M | +47.71% |
| Q3 2025 | 2025-09-30 | $35.3M | $14.0M | +66.03% |
| Q2 2025 | 2025-06-30 | $36.9M | $15.4M | +71.29% |
| Q1 2025 | 2025-03-31 | $30.6M | $13.0M | +73.66% |
| Q4 2024 | 2024-12-31 | $24.4M | $11.0M | +82.57% |
| Q3 2024 | 2024-09-30 | $21.3M | $8.0M | +60.85% |
| Q2 2024 | 2024-06-30 | $21.6M | $9.0M | +71.86% |
| Q1 2024 | 2024-03-31 | $17.6M | $8.0M | +82.72% |
| Q4 2023 | 2023-12-31 | $13.3M | $6.3M | +90.44% |
| Q3 2023 | 2023-09-30 | $13.2M | $6.6M | +98.86% |
| Q2 2023 | 2023-06-30 | $12.5M | $6.7M | +112.83% |
| Q1 2023 | 2023-03-31 | $9.6M | $5.5M | +135.37% |
| Q4 2022 | 2022-12-31 | $7.0M | $3.9M | +121.94% |
| Q3 2022 | 2022-09-30 | $6.6M | $3.7M | +126.35% |
| Q2 2022 | 2022-06-30 | $5.9M | $3.1M | +112.86% |
| Q1 2022 | 2022-03-31 | $4.1M | $2.2M | +119.79% |
| Q4 2021 | 2021-12-31 | $3.2M | $1.2M | +63.20% |
| Q3 2021 | 2021-09-30 | $2.9M | $1.1M | +59.79% |
| Q2 2021 | 2021-06-30 | $2.8M | $1.5M | +114.82% |
| Q1 2021 | 2021-03-31 | $1.9M | $1.5M | +401.34% |
| Q4 2020 | 2020-12-31 | $1.9M | — | — |
| Q3 2020 | 2020-09-30 | $1.8M | $1.6M | +593.58% |
| Q2 2020 | 2020-06-30 | $1.3M | — | — |
| Q1 2020 | 2020-03-31 | $372,000 | — | — |
| Q3 2019 | 2019-09-30 | $265,000 | — | — |
Vaxcyte stock-based compensation trends
Over the last five fiscal years, Vaxcyte's stock-based compensation increased from $5.4M to $138.8M, a change of $133.4M. The latest reported quarter, Q2 2026, shows $41.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaxcyte source filings ↗